BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  Boehringer  Ingelheim  International  GmbH  submitted  on  3  November  2004  an 
application  for  Marketing  Authorisation to the  European Medicines  Agency  (EMEA)  for  APTIVUS 
250 mg soft capsules through the centralised procedure. After agreement by the CHMP on 24 March 
2004,  this  medicinal  product  has  been  referred  to  Part  B  of  the  Annex  to  Council  Regulation  No 
(EEC) 2309/93 of 22 July 1993 as amended. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur:  Dr. E. Abadie 
Co-Rapporteur:  Dr. G. Kreutz 
Scientific Advice: 
The applicant received Scientific Advice from the CHMP on 25 January 2001 and 18 January 2002. 
The Scientific Advice pertained to non-clinical and clinical aspects of the dossier.  
Licensing status: 
The product was not licensed in any country at the time of submission of the application. It was 
licensed in the USA on 22 June 2005, in Mexico on 19 July 2005 and in Switzerland on 25 August 
2005. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 3 November 2004.  
The procedure started on 15 November 2004. 
The Rapporteur's first Assessment Report was circulated to all CHMP members on 25 January 
2005. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 25 
January 2005). 
During  the  meeting  on  14  –  17  March  2005,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 17 March 2005. 
The applicant submitted the responses to the CHMP consolidated List of Questions on 15 April 
2005. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 3 June 2005. 
During  the  CHMP  meeting  on  20-23  June  2005,  the  CHMP  agreed  on  a  list  of  outstanding 
issues to be addressed in writing and/or in an oral explanation by the applicant. 
The applicant submitted the responses to the CHMP list of outstanding issues on 1 July 2005. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the list 
of outstanding issues to all CHMP members on 19 July 2005. 
During the meeting on 25 – 27 July 2005, the CHMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing  Authorisation  under  exceptional  circumstances to  APTIVUS  on 27 July 2005. The 
applicant provided the letter of undertaking on the specific obligations and follow-up measures 
to be fulfilled post-authorisation on 27 July 2005. 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 25 October 2005. 
1/1 

EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
